Le Lézard
Classified in: Health
Subjects: RCL, CFG

Public advisory - Unauthorized Kobayashi Eyebon Eye Wash seized from Oceanbuy store and removed from website because it may pose serious health risks


OTTAWA, ON, Febr. 22, 2023 /CNW/ - 

Brand: Kobayashi Eyebon Eye Wash

Summary
Images

Kobayashi Eyebon Eye Wash,  Cool format (CNW Group/Health Canada)

Affected products

Product

Prescription drug on the label

Retailer

Kobayashi Eyebon Eye Wash,  Cool format

Labelled in Japanese to contain aminocaproic acid

Oceanbuy

2600 John St., Unit #107

Markham, ON

Issue

Health Canada is warning consumers about an unauthorized health product, Kobayashi Eyebon Eye Wash, Cool format, which it seized from Oceanbuy, a store located in Markham ON, and removed from online sale. The unauthorized product was labelled in Japanese to contain aminocaproic acid, a prescription drug used to decrease bleeding in various clinical situations.

The product is promoted as an eye wash for contact lens users and for the prevention of eye disease.

Exposure to aminocaproic acid in the eye may affect the eye itself, and the acid may be absorbed through the tear ducts into the blood. Side effects may include watery eyes, blurry or reduced vision, headache, dizziness, nausea, muscle weakness and skin rash.

Selling unauthorized health products in Canada is illegal. Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks. For example, they could contain high-risk ingredients, such as prescription drugs, additives or contaminants that may or may not be listed on the label. These ingredients could interact with other medications and foods. In addition, these products may not actually contain the active ingredients that consumers would expect them to contain to help maintain and improve their health.

Prescription drugs should only be used under the advice and supervision of a health care professional because they are used to treat specific conditions and may cause serious side effects.

 What you should do

Également disponible en français

SOURCE Health Canada


These press releases may also interest you

at 18:27
Andreozzi + Foote is deeply troubled by revelations of sexual abuse perpetrated by Ramon Garcia against patients at Carbon Health Urgent Care in Jenkintown and possibly other locations. Our client, Jane Doe, bravely stepped forward to share her...

at 18:14
SARC (Sarcoma Alliance for Research Through Collaboration) is proud to announce the launch of the Sarcoma Centers Registry https://sarctrials.org/sarcoma-centers/, a comprehensive, global resource facilitating...

at 18:08
Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced with great respect and sorrow the unexpected passing last night of...

at 18:02
It takes a unique, special kind of dedication to become a nurse. For the nurses in First Nations and Inuit communities, it takes strength, resiliency, expertise, and most importantly, heart. It takes an understanding of the complex environment of...

at 17:44
On Tuesday, May 7, 2024, The Center for Discovery® (TCFD, The Center) honored Edward C. Sweeney, TCFD Board Chair, at the 24th annual Evening of Discovery Gala. The Gala was hosted by Mo Rocca, CBS Sunday Morning Correspondent, Humorist, and Creator...

at 17:30
PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibodyThe clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the...



News published on and distributed by: